Synergene Therapeutics, Inc.

This study was designed to test a new drug called SGT-53 combined with radiation and chemotherapy in children whose brain or spinal cord tumors had come back or were not responding to treatment. The goal was to see if the combination was safe and could shrink tumors. However, the…

This early-stage study tests a new drug called SGT-53, given alone or with chemotherapy, in children and young adults (ages 1-21) with solid tumors that have come back or not responded to treatment. The main goals are to find safe doses and understand side effects. The study is c…